MRI for Inflammatory Breast Cancer (IBC)

Phase-Based Progress Estimates

Effectiveness

Safety

Inflammatory Breast Cancer (IBC)+9 More

MRI - Device

You have a chance of qualifying for this trial. We made sure your application will take less than 5 minutes.

Eligibility

18+

All Sexes

What conditions do you have?

Select

Eligibility

18+

All Sexes

What conditions do you have?

Select

Study Summary

This trial is testing if MRI can find brain metastases in people with breast cancer.

Eligible Conditions

Inflammatory Breast Cancer (IBC)
Breast Cancer (Triple Negative Breast Cancer (TNBC))
Breast
Malignant Neoplasms
Breast Cancer
erbB-2 Receptor

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Inflammatory Breast Cancer (IBC)

Vic-trastuzumab duocarmazine (SYD985) + paclitaxel

Chimeric Antigen Receptor T-Cell Therapy

Talazoparib

Study Objectives

3 Primary · 16 Secondary · Reporting Duration: Through study completion, an average of 1 year

12 Months

Neurologic Quality of Life at 12 Months using the MD Anderson Symptom Inventory - Brain Tumor Module

Year 1

All-cause mortality

Development of leptomeningeal carcinomatosis as seen on magnetic resonance imaging of the brain

Development of metastases in the brainstem as seen on magnetic resonance imaging of the brain

Development of seizures based on review of medical notes / history

Development of symptomatic brain metastases based on review of medical notes / history

Incidence of Brain Metastases

Incidence of Symptomatic Brain Metastases

Neurocognitive function using the Controlled Oral Word Association Test

Neurocognitive function using the Hopkins Verbal Learning Test Instrument

Neurocognitive function using the Mini-Mental Status Exam Instrument

Neurocognitive function using the Trail Making Test Instrument

Neurologic death

Number of brain metastases

Quality of life assessment via EuroQol Group 5D Instrument

Radiographic appearance of brain metastases

Receipt of neurosurgical resection due to brain metastases

Brain

Size of brain metastases

Trial Safety

Safety Progress

1 of 3

Other trials for Inflammatory Breast Cancer (IBC)

Vic-trastuzumab duocarmazine (SYD985) + paclitaxel

Chimeric Antigen Receptor T-Cell Therapy

Talazoparib

Trial Design

4 Treatment Groups

HR+ or HER2+ Metastatic Breast Cancer - No Screening Arm

1 of 4

Triple Negative Breast Cancer

1 of 4

Inflammatory Breast Cancer Managed with Curative Intent

1 of 4

HR+ or HER2+ Metastatic Breast Cancer - Screening Arm

1 of 4

Active Control

Experimental Treatment

214 Total Participants · 4 Treatment Groups

Primary Treatment: MRI · No Placebo Group · N/A

Triple Negative Breast Cancer

Device

Experimental Group · 1 Intervention: MRI · Intervention Types: Device

Inflammatory Breast Cancer Managed with Curative Intent

Device

Experimental Group · 1 Intervention: MRI · Intervention Types: Device

HR+ or HER2+ Metastatic Breast Cancer - Screening Arm

Device

Experimental Group · 1 Intervention: MRI · Intervention Types: Device

HR+ or HER2+ Metastatic Breast Cancer - No Screening ArmNoIntervention Group · 1 Intervention: HR+ or HER2+ Metastatic Breast Cancer - No Screening Arm · Intervention Types:

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

MRI

2009

Completed Phase 2

~1370

Trial Logistics

Trial Timeline

Approximate Timeline

Screening: ~3 weeks

Treatment: Varies

Reporting: through study completion, an average of 1 year

Who is running the clinical trial?

Conquer Cancer FoundationOTHER

11 Previous Clinical Trials

1,034 Total Patients Enrolled

Dana-Farber Cancer InstituteLead Sponsor

1,012 Previous Clinical Trials

393,145 Total Patients Enrolled

3 Trials studying Inflammatory Breast Cancer (IBC)

95 Patients Enrolled for Inflammatory Breast Cancer (IBC)

Ayal Aizer, MD, MHSPrincipal Investigator - Brigham and Women's Hospital

Brigham & Women's Hospital, Brigham and Women's Physicians Organization, Dana-Farber Cancer Institute

Yale University School Of Medicine (Medical School)

1 Previous Clinical Trials

112 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

You have histologically or cytologically confirmed breast cancer with pathologic assessment of estrogen receptor (ER), progesterone receptor (PR), and (human epidermal growth factor receptor 2 (HER2) status.

You have a life expectancy of greater than 12 weeks.

Participants must be able to understand and sign a written informed consent document.

About The Reviewer

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: October 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References